ValuEngine upgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a buy rating to a strong-buy rating in a report released on Thursday, ValuEngine reports.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Nektar Therapeutics from a buy rating to a hold rating and set a $34.00 target price on the stock. in a research report on Wednesday. William Blair reissued a buy rating on shares of Nektar Therapeutics in a research report on Friday, June 14th. Cowen set a $82.00 target price on shares of Nektar Therapeutics and gave the company a buy rating in a research report on Thursday, June 13th. BidaskClub downgraded shares of Nektar Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, July 16th. Finally, Mizuho cut their target price on shares of Nektar Therapeutics from $81.00 to $79.00 and set a buy rating on the stock in a research report on Friday, July 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $67.60.
NKTR traded down $0.10 on Thursday, reaching $31.09. 2,336,162 shares of the company traded hands, compared to its average volume of 1,457,576. Nektar Therapeutics has a one year low of $28.04 and a one year high of $69.76. The firm has a fifty day moving average price of $33.40. The firm has a market capitalization of $5.44 billion, a P/E ratio of 8.22 and a beta of 2.68. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.03. The business had revenue of $28.22 million for the quarter, compared to the consensus estimate of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter last year, the firm posted ($0.60) EPS. Equities research analysts expect that Nektar Therapeutics will post -3.13 earnings per share for the current year.
In other news, SVP Stephen K. Doberstein sold 3,461 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $108,571.57. Following the transaction, the senior vice president now owns 95,913 shares of the company’s stock, valued at approximately $3,008,790.81. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Jillian B. Thomsen sold 1,928 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $60,481.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 253,283 shares of company stock worth $8,356,254. Insiders own 4.02% of the company’s stock.
Several institutional investors have recently modified their holdings of NKTR. Qube Research & Technologies Ltd acquired a new stake in Nektar Therapeutics during the 2nd quarter valued at approximately $328,000. Comerica Bank lifted its stake in shares of Nektar Therapeutics by 3.4% in the 2nd quarter. Comerica Bank now owns 32,468 shares of the biopharmaceutical company’s stock valued at $1,038,000 after purchasing an additional 1,062 shares during the period. Kavar Capital Partners LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at $44,000. DekaBank Deutsche Girozentrale lifted its stake in shares of Nektar Therapeutics by 69.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 162,316 shares of the biopharmaceutical company’s stock valued at $5,656,000 after purchasing an additional 66,374 shares during the period. Finally, Coastal Investment Advisors Inc. lifted its stake in shares of Nektar Therapeutics by 334.3% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,937 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 1,491 shares during the period. 92.14% of the stock is currently owned by hedge funds and other institutional investors.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Further Reading: What are gap-up stocks?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.